| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 13/01/2025 | 15:00 | GlobeNewswire Inc. | Biomea Fusion to Become a Diabetes & Obesity Medicines Company | NASDAQ:BMEA | Biomea Fusion Inc |
| 07/01/2025 | 15:00 | GlobeNewswire Inc. | Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study | NASDAQ:BMEA | Biomea Fusion Inc |
| 06/01/2025 | 22:57 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:BMEA | Biomea Fusion Inc |
| 06/01/2025 | 13:00 | GlobeNewswire Inc. | Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference | NASDAQ:BMEA | Biomea Fusion Inc |
| 20/12/2024 | 21:06 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BMEA | Biomea Fusion Inc |
| 17/12/2024 | 14:10 | GlobeNewswire Inc. | Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes | NASDAQ:BMEA | Biomea Fusion Inc |
| 17/12/2024 | 00:15 | GlobeNewswire Inc. | Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) | NASDAQ:BMEA | Biomea Fusion Inc |
| 12/12/2024 | 23:02 | GlobeNewswire Inc. | Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) | NASDAQ:BMEA | Biomea Fusion Inc |
| 09/12/2024 | 22:01 | GlobeNewswire Inc. | Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia | NASDAQ:BMEA | Biomea Fusion Inc |
| 06/12/2024 | 14:00 | GlobeNewswire Inc. | Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia | NASDAQ:BMEA | Biomea Fusion Inc |
| 02/12/2024 | 22:05 | GlobeNewswire Inc. | Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BMEA | Biomea Fusion Inc |
| 18/11/2024 | 14:00 | GlobeNewswire Inc. | Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) | NASDAQ:BMEA | Biomea Fusion Inc |
| 30/10/2024 | 21:00 | GlobeNewswire Inc. | Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate | NASDAQ:BMEA | Biomea Fusion Inc |
| 29/10/2024 | 22:19 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:BMEA | Biomea Fusion Inc |
| 29/10/2024 | 21:46 | GlobeNewswire Inc. | Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights | NASDAQ:BMEA | Biomea Fusion Inc |
| 21/10/2024 | 15:00 | GlobeNewswire Inc. | Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 | NASDAQ:BMEA | Biomea Fusion Inc |
| 15/10/2024 | 22:05 | GlobeNewswire Inc. | Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 R | NASDAQ:BMEA | Biomea Fusion Inc |
| 07/10/2024 | 15:00 | GlobeNewswire Inc. | Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) | NASDAQ:BMEA | Biomea Fusion Inc |
| 01/10/2024 | 22:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BMEA | Biomea Fusion Inc |
| 01/10/2024 | 15:00 | GlobeNewswire Inc. | Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts | NASDAQ:BMEA | Biomea Fusion Inc |
| 26/09/2024 | 20:00 | GlobeNewswire Inc. | FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials | NASDAQ:BMEA | Biomea Fusion Inc |
| 31/07/2024 | 22:05 | GlobeNewswire Inc. | Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights | NASDAQ:BMEA | Biomea Fusion Inc |
| 06/06/2024 | 22:05 | GlobeNewswire Inc. | Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold | NASDAQ:BMEA | Biomea Fusion Inc |
| 30/05/2024 | 15:12 | GlobeNewswire Inc. | Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes | NASDAQ:BMEA | Biomea Fusion Inc |
| 02/05/2024 | 22:05 | GlobeNewswire Inc. | Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights | NASDAQ:BMEA | Biomea Fusion Inc |
| 01/05/2024 | 22:10 | GlobeNewswire Inc. | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BMEA | Biomea Fusion Inc |
| 01/04/2024 | 15:02 | GlobeNewswire Inc. | Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219 | NASDAQ:BMEA | Biomea Fusion Inc |
| 01/04/2024 | 15:00 | GlobeNewswire Inc. | Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights | NASDAQ:BMEA | Biomea Fusion Inc |
| 06/03/2024 | 09:04 | GlobeNewswire Inc. | Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function | NASDAQ:BMEA | Biomea Fusion Inc |
| 01/03/2024 | 22:16 | GlobeNewswire Inc. | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BMEA | Biomea Fusion Inc |